Compare stocks

PRFX vs SKYE

PRF Technologies Ltd. Ordinary Shares and Skye Bioscience, Inc. Common Stock

Compare the businesses

PRF Technologies Ltd. Ordinary Shares

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.

Open PRFX dashboard ↗

Skye Bioscience, Inc. Common Stock

Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

Open SKYE dashboard ↗

Sign in to keep comparing stocks

You've viewed 3 distinct stock or comparison pages today. Sign in for 10 views per day.

3 of 3 daily views used. Your allowance resets at midnight Eastern time. Refreshes and chart changes do not use another view.

New to NexusTrade? Create a free account.

Choose another comparison ↗